The European licensure of 4CMenB, the first vaccine licensed to prevent non-epidemic meningococcal B (MenB) disease, marked an important milestone in the fight against meningococcal disease. However, the potential introduction of 4CMenB into the routine infant schedule is complicated by a number of factors. The recent decline in the number of cases of invasive MenB disease in the UK has important implications for cost effectiveness, though the unpredictable nature of meningococcal disease epi...Expand abstract
- Publisher copy:
- Copyright date:
Will booster doses be required for serogroup B meningococcal vaccine?
If you are the owner of this record, you can report an update to it here: Report update to this record